Andreas Sidiropoulos

Dr. Andreas Sidiropoulos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSotirios Sotiriou
Sotirios Sotiriou
Athina A SamaraAthina A Samara
Athina A Samara
DVDimitra Vamvakopoulou
Dimitra Vamvakopoulou
KVKonstantinos-Odysseas Vamvakopoulos
Konstantinos-Odysseas Vamvakopoulos
ASAndreas Sidiropoulos
Andreas Sidiropoulos
Stylianos BoutlasStylianos Boutlas
Stylianos Boutlas
Background: β-Thalassemia is the most prevalent single gene blood disorder, while the assessment of its susceptibility to coronavirus disease 2019 (COVID-19) warrants it a pressing biomedical priority. Methods: We studied 255 positive COVID-19 participants unvaccinated against severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), consecutively recruited during the last trimester of 2020. Patient characteristics including age, sex, current smoking status, atrial fibrillation, chronic respiratory disease, coronary disease, diabetes, neoplasia, hyperlipidemia, hypertension, and β-thalassemia heterozygosity were assessed for COVID-19 severity, length of hospitalization, intensive care unit (ICU) admission and mortality from COVID-19. Results: We assessed patient characteristics associated with clinical symptoms, ICU admission, and mortality from COVID-19. In multivariate analysis, severe-critical COVID-19 was strongly associated with male sex (p = 0.023), increased age (p < 0.001), and β-thalassemia heterozygosity (p = 0.002, OR = 2.89). Regarding the requirement for ICU care, in multivariate analysis there was a statistically significant association with hypertension (p = 0.001, OR = 5.12), while β-thalassemia heterozygosity had no effect (p = 0.508, OR = 1.33). Mortality was linked to male sex (p = 0.036, OR = 2.09), increased age (p < 0.001) and β-thalassemia heterozygosity (p = 0.010, OR = 2.79) in multivariate analysis. It is worth noting that hyperlipidemia reduced mortality from COVID-19 (p = 0.008, OR = 0.38). No statistically significant association of current smoking status with patient characteristics studied was observed. Conclusions: Our pilot observations indicate enhanced mortality of β-thalassemia heterozygotes from COVID-19.

19 June 2024
Verified
Journal Article
Open access
ASAndreas Sidiropoulos
Andreas Sidiropoulos
Jscholar is an open access publisher of peer reviewed journals and research articles, which are free to access, share and distribute for the advancement of scholarly communication.